(Head office: Suita City, Osaka; Representative Director: Yosuke Tochihara), which is engaged in the development of drugs targeting pathological periostin mutants, announces that it will provide its developed antibody (Osaka University Hospital), for an investigator-initiated clinical trial (for metastatic or recurrent HER2-negative breast cancer patients).

With regard to the research and development led by Osaka University Hospital, Periotherapia has been working on the development with the support of the AMED Drug Discovery Venture Ecosystem Enhancement Project, investors and various stakeholders. We will continue to further accelerate the development.

For a press release by Osaka University on this clinical trial, see
https://www.med.osaka-u.ac.jp/archives/42863

For more information, see the press release below.
PR TIMES

An article on the case has also been published in Nikkei Biotech.
Please take a look.
https://bio.nikkeibp.co.jp/atcl/news/p1/25/03/12/13071/